Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study

• Main Authors: Jan Lewis Brandes (Author), Suzanne Klise (Author), John H Krege (Author), Michael Case (Author), Rashna Khanna (Author), Raghavendra Vasudeva (Author), Joel Raskin (Author), David Kudrow (Author)
• Format: Book
• Published: SAGE Publishing, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation. A total of 2030 patients received ≥1 lasmidit...